Thermo Fisher completes $17.4B acquisition of clinical research firm PPD, Inc.

THERMO FISHER SCIENTIFIC INC.

Total consideration $17.4 billion; PPD common stock ceased trading on Nasdaq.
Deal expected to contribute $1.50 to Thermo Fisher's adjusted EPS in 2022.
Synergies of ~$125M by year three: $75M cost, $50M revenue-related.
Thermo Fisher assumes ~$3.0B net debt of PPD, all retired at closing.
PPD to join Laboratory Products and Services Segment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.